Last reviewed · How we verify
NCT05212532
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
Phase 1 trial testing EOM613 in COVID-19 Pneumonia in 40 participants. Status unknown.
28 February 2022
Quick facts
| Lead sponsor | EOM Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 9 August 2021 |
| Primary completion | 28 February 2022 |
| Estimated completion | 30 March 2022 |
| Sites | 4 locations across Brazil |
Drugs / interventions tested
- EOM613 — full drug profile →
Conditions studied
- COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
Sponsor
EOM Pharmaceuticals — full company profile →
Who can join
Adults 18 to 84, any sex, with COVID-19 Pneumonia or COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Treatment of Human Glioblastoma U251 Cells with Sulforaphane and a Peptide Nucleic Acid (PNA) Targeting miR-15b-5p: Synergistic Effects on Induction of Apoptosis.
Gasparello J, Papi C, Zurlo M, Gambari L, et al · · 2022 · cited 19× · PMID 35209084 · DOI 10.3390/molecules27041299
Verify or expand the search:
- PubMed search for NCT05212532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Pneumonia
Currently open trials in the same condition.
- NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
- NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05212532 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EOM Pharmaceuticals
- Last refreshed: 28 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05212532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing